Abstract
Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expansion Phase
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have